ZA200206550B - Compositions useful for regulating parkin gene activity. - Google Patents
Compositions useful for regulating parkin gene activity. Download PDFInfo
- Publication number
- ZA200206550B ZA200206550B ZA200206550A ZA200206550A ZA200206550B ZA 200206550 B ZA200206550 B ZA 200206550B ZA 200206550 A ZA200206550 A ZA 200206550A ZA 200206550 A ZA200206550 A ZA 200206550A ZA 200206550 B ZA200206550 B ZA 200206550B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- nucleic acid
- peptide
- protein
- new
- Prior art date
Links
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 title claims description 37
- 239000000203 mixture Substances 0.000 title claims description 12
- 230000000694 effects Effects 0.000 title description 10
- 230000001105 regulatory effect Effects 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 59
- 150000001875 compounds Chemical class 0.000 claims description 50
- 102000045222 parkin Human genes 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 150000007523 nucleic acids Chemical class 0.000 claims description 35
- 108020004707 nucleic acids Proteins 0.000 claims description 33
- 102000039446 nucleic acids Human genes 0.000 claims description 33
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 230000003993 interaction Effects 0.000 claims description 21
- 101100434045 Danio rerio acp7 gene Proteins 0.000 claims description 18
- 101100434047 Mus musculus Acp7 gene Proteins 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 102100027336 Regenerating islet-derived protein 3-alpha Human genes 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 15
- 229920001184 polypeptide Polymers 0.000 claims description 15
- 101710176122 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000000523 sample Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000007170 pathology Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 239000012636 effector Substances 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims 3
- 230000000626 neurodegenerative effect Effects 0.000 claims 3
- 101000581815 Homo sapiens Regenerating islet-derived protein 3-alpha Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 102000049256 human REG3A Human genes 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 23
- 208000018737 Parkinson disease Diseases 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000002452 interceptive effect Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 102000044159 Ubiquitin Human genes 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000004558 lewy body Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000003523 substantia nigra Anatomy 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- -1 or a homolog thereof Proteins 0.000 description 2
- 108700007244 parkin Proteins 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 description 1
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000023715 cellular developmental process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000008560 physiological behavior Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 108060008004 synaptotagmin Proteins 0.000 description 1
- 102000003137 synaptotagmin Human genes 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0001980A FR2805266B1 (fr) | 2000-02-17 | 2000-02-17 | Compositions utilisables pour reguler l'activite de la parkine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200206550B true ZA200206550B (en) | 2003-12-19 |
Family
ID=8847103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200206550A ZA200206550B (en) | 2000-02-17 | 2002-08-15 | Compositions useful for regulating parkin gene activity. |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP4861590B2 (da) |
| DK (1) | DK1259606T3 (da) |
| ES (1) | ES2345318T3 (da) |
| FR (1) | FR2805266B1 (da) |
| PT (1) | PT1259606E (da) |
| ZA (1) | ZA200206550B (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116254286B (zh) * | 2022-12-23 | 2024-07-12 | 厦门大学 | 氰胺诱导的酿酒酵母工程菌及其构建方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2449501A (en) * | 1999-12-21 | 2001-07-03 | Incyte Genomics, Inc. | Vesicle trafficking proteins |
-
2000
- 2000-02-17 FR FR0001980A patent/FR2805266B1/fr not_active Expired - Fee Related
-
2001
- 2001-02-15 JP JP2001560240A patent/JP4861590B2/ja not_active Expired - Fee Related
- 2001-02-15 PT PT01907820T patent/PT1259606E/pt unknown
- 2001-02-15 DK DK01907820.3T patent/DK1259606T3/da active
- 2001-02-15 ES ES01907820T patent/ES2345318T3/es not_active Expired - Lifetime
-
2002
- 2002-08-15 ZA ZA200206550A patent/ZA200206550B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2345318T3 (es) | 2010-09-21 |
| FR2805266A1 (fr) | 2001-08-24 |
| FR2805266B1 (fr) | 2004-12-03 |
| JP4861590B2 (ja) | 2012-01-25 |
| JP2003523193A (ja) | 2003-08-05 |
| PT1259606E (pt) | 2010-08-02 |
| DK1259606T3 (da) | 2010-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2320220C (en) | Isolated dna or gene responsible for parkinson's disease | |
| JP2002281985A (ja) | Ｍｂｇｐ１ポリペプチドおよびポリヌクレオチド | |
| JPH1175873A (ja) | 新規化合物 | |
| WO2000010583A1 (en) | Human histone deacetylase gene hd4 | |
| JP2008281545A (ja) | ヒトグリシン輸送体 | |
| US6362326B1 (en) | 11 cby genomic sequence | |
| ZA200206550B (en) | Compositions useful for regulating parkin gene activity. | |
| JP2002281989A (ja) | Ｆｒｉｚｚｌｅｄ−３ポリペプチドおよびポリヌクレオチド | |
| JPH1156376A (ja) | ヒトＩκＢ−β | |
| CA2408374A1 (en) | Mutation in the .beta.2 nicotinic acetylcholine receptor subunit associated with nocturnal frontal lobe epilepsy | |
| JP2003529371A (ja) | ヒトセリンラセマーゼ | |
| JP2002543833A (ja) | 海馬で発現する分子 | |
| WO1999042576A1 (en) | Cerebellin-2 related polypeptides and dna coding therefor | |
| JP2002517259A (ja) | Ａｃｒｐ３０（３０ｋｄ脂肪細胞補体関連タンパク質）の相同体ａｃｒｐ３０ｒ２ | |
| JP2002507413A (ja) | サイトカインファミリーのメンバー，２−２１ | |
| NZ520802A (en) | Compositions useful for regulating parkin gene activity | |
| AU2615602A (en) | Application of aprataxin gene to diagnosis and treatment for early-onset spinocerebellar ataxia (EAOH) | |
| JPH11206391A (ja) | ヒトｌｉｇ−１相同体（ｈｌｉｇ−１） | |
| US5770432A (en) | Obesity associated genes | |
| EP1098970A1 (en) | Human sbpsapl gene with homology to the prosaposin family of neurotrophic factors | |
| WO2000017349A1 (en) | A HUMAN Hsg III GENE | |
| JPH1132783A (ja) | Ｈｆｉｚｇ５３ポリヌクレオチドおよびポリペプチド | |
| JPH1132782A (ja) | Ｙｎｌ０７５ｗ／ｈｔｘｆｔ１９ポリヌクレオチドおよびポリペプチド | |
| CA2340617A1 (en) | Genes associated with neurotransmitter processing | |
| JP2005532035A (ja) | 膜貫通型タンパク質 |